10 BenkhouchaM.Santiago-RaberM
VCM monitored performance metrics, optimized strategies where needed, and ensured both Marian and Nuwhites brand objectives were met
[Abstract]2025 May;31(5):111
Explore the latest in obesity treatment with our retatrutide vs semaglutide vs tirzepatide comparison, revealing which weight loss peptide stands out in this competitive and promising field
Global regulatory frameworksespecially the ICH S1 series guidelinesrequire structured carcinogenicity assessment: ICH S1A/S1B/S1C define when lifetime rodent studies are required Emphasis on hazard identification rather than direct human prediction Adoption of Weight-of-Evidence (WoE) approaches in ICH S1B(R1) The updated S1B(R1) guideline specifically encourages: Integration of mechanistic, exposure, and translational data Reduced reliance on 2-year rodent bioassays when justified Greater emphasis on human relevance and multi-factor evidence This shift reflects a broader regulatory evolution toward mechanism-based safety assessment rather than purely animal-driven hazard signals
We've seen a significant, sometimes dramatic shift in how people approach weight loss, moving toward powerful medical tools like Semaglutide and Tirzepatide